<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Psychiatry">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Psychiatry</JournalTitle>
      <Issn>1735-4587</Issn>
      <Volume>2</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2007</Year>
        <Month>09</Month>
        <Day>15</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Evaluating the Effect of 8-Week Treatment With Risperidone On Fasting Blood Glucose of Patients with Schizophrenia</title>
    <FirstPage>124</FirstPage>
    <LastPage>126</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Firouzeh</FirstName>
        <LastName>Raisi</LastName>
        <affiliation locale="en_US">Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran&#xD;
Psychiatry &amp; Psychology Research Center, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Hadi</FirstName>
        <LastName>Okhovatpoor</LastName>
        <affiliation locale="en_US">Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Simin</FirstName>
        <LastName>Dashti-Khavidaki</LastName>
        <affiliation locale="en_US">Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Hossein</FirstName>
        <LastName>Khalili</LastName>
        <affiliation locale="en_US">Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Padideh</FirstName>
        <LastName>Ghaeli</LastName>
        <affiliation locale="en_US">Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran&#xD;
Psychiatry &amp; Psychology Research Center, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>17</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Objective: This study was designed to evaluate the effects of risperidone on fasting blood glucose (FBG) in patients with Schizophrenia .
 Method: Seventy five non-diabetic patients with Schizophrenia (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) entered this cross-sectional study. Patients did not receive any medications (Including risperidone) affecting serum FBG levels for at least 2 weeks prior to the initiation of the study. Patients received the mean dose of 4.5mg (range 2-12mg) risperidone for 8 weeks. Pregnant women, patients with diabetes mellitus and a history of any major heart disease were excluded from this study.Additionally, none of the patients should have received electroconvulsive therapy within 6 months prior to the initiation of the antiphsychotics.FBG levels were measured at the initiation and 8 weeks after starting risperidone.
Results: Fifty one patients completed the study. The mean FBG level was increased from 88.9mg/dL (baseline) to 94.4 mg/dL at week 8 (P =0.003). This 8-week study showed that FBG levels may increase in schizophrenic patients receiving risperidone.
Conclusion: Measuring and monitoring FBG before the initiation and during the treatment with risperidone is suggested.</abstract>
    <web_url>https://ijps.tums.ac.ir/index.php/ijps/article/view/450</web_url>
    <pdf_url>https://ijps.tums.ac.ir/index.php/ijps/article/download/450/444</pdf_url>
  </Article>
</Articles>
